Am J Transplant, Volume 21, Suppl 3 Archives - ATC Abstracts

2021 American Transplant Congress
Validation of a Novel Gene Expression Biomarker of Rejection Following Liver Transplantation
J. Levitsky¹, M. Kandpal¹, T. Whisenant², K. Guo¹, S. Kurian³, M. Abecassis⁴
¹Gastroenterology & Hepatology; Comprehensive Transplant Center, Northwestern University, Chicago, IL, ²University of California San Diego, San Diego, CA, ³Scripps Clinic, La Jolla, CA, ⁴University of Arizona College of Medicine Tucson, Tucson, AZ
*Purpose: Non-invasive biomarkers distinguishing early signs of immune activation vs. quiescence could more objectively guide immunosuppression management after liver transplantation (LT). Our aim was to…
2021 American Transplant Congress
The Rate of Hospitalization Among Patients with Cirrhosis is More Than Twice as High as Patients Over 85 Years
N. R. Mazumder¹, K. Guo², L. Zhao³, A. Kho¹, K. Walters⁴, T. S. Carey⁴, C. Loftus¹, D. P. Ladner¹
¹Northwestern Memorial Hospital, Chicago, IL, ²Biostatistics, Northwestern Memorial Hospital, Chicago, IL, ³Biostatistcs, Northwestern Memorial Hospital, Chicago, IL, ⁴University of North Carolina Chapel Hill, Chapel Hill, NC
*Purpose: Cirrhosis is a common disease however it is understudied because population data on patients with cirrhosis is lacking. While the risk of hospitalization in…
2021 American Transplant Congress
Economic and Clinical Benefit of Cmv Matching in Kidney Transplantation
D. Axelrod¹, S. Chang², A. Olyaei³, D. Malinoski³, D. Norman³, K. Lentine⁴, M. Schnitzler⁴, D. Segev⁵, J. Lockridge³
¹Univ of Iowa, Iowa City, IA, ²Washington Univ, Seattle, WA, ³Oregon Health Sciences Univ, Portland, OR, ⁴Saint Louis Univ, Saint Louis, MO, ⁵Johns Hopkins, Baltimore, MD
*Purpose: Recently, kidney transplant (KTx) centers in Oregon collaborated to preferentially allocate cytomegalovirus-seronegative (CMV D-) kidneys to seronegative recipients (CMV R-), successfully reducing high-risk CMV…
2021 American Transplant Congress
Desensitization Using Clazakizumab® (anti-il-6) in Highly-hla Sensitized Patients Awaiting Kidney Transplant (nct03380962)
A. A. Vo¹, N. Ammerman¹, E. Huang¹, M. Toyoda², S. Ge², A. Peng¹, R. Najjar¹, S. Sethi¹, S. Williamson¹, C. Myers¹, K. Lim¹, M. Gillespie¹, S. Jordan¹
¹Kidney Transplant, Cedars Sinai Medical Ctr, Los Angeles, CA, ²Transplant Immunology Laboratory, Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: IL-6 is a critical cytokine for plasma cell IgG production. Clazakizumab (CSL Behring LLC) is a humanized monoclonal aimed at the cytokine IL-6. Here…
2021 American Transplant Congress
Impact of Transplant Center Volume on Utilization of and Outcomes Following Donation After Circulatory Death Liver Transplantation in the United States
S. Kumar¹, S. Lin², J. D. Schold²
¹Digestive Disease Institute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates, ²Department of Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH
*Purpose: Despite increased utilization of donation after circulatory death (DCD) grafts in the US, impact of center volume on DCD liver transplantation (LT) remains unclear.…
2021 American Transplant Congress
Liver Simulated Allocation Model Does Not Accurately Predict Organ Offer Decisions in Pediatric Liver Transplant Candidates
N. L. Wood¹, D. B. Mogul², E. K. Hsu³, E. R. Perito⁴, G. V. Mazariegos⁵, D. Vanderwerken¹, D. L. Segev², S. Gentry¹
¹US Naval Academy, Annapolis, MD, ²Johns Hopkins, Baltimore, MD, ³Univ of Washington, Seattle, WA, ⁴UCSF, San Francisco, CA, ⁵Univ of Pittsburgh, Pittsburgh, PA
*Purpose: The U.S. relies on the Scientific Registry of Transplant Recipient’s (SRTR’s) Liver Simulated Allocation Model (LSAM) to predict the effect of allocation policy changes…
2021 American Transplant Congress
Growing LDLT Volumes at a US Center- What Does It Take to Do Over 100 LDLTs Per Year
A. Humar, C. Hughes, G. Mazariegos, K. Soltys, A. Gallatin, K. Emmett, A. Tevar, M. Molinari, A. Ganoza, V. Gunabushanam, S. Ganesh
University of Pittsburgh, Pittsburgh, PA
*Purpose: LDLT remains underutilized in the US, accounting for
2021 American Transplant Congress
Effective Patient Throughput on the Transplant Surgery Service
E. M. Thomas¹, P. K. Shah¹, S. Beasley², A. Saad¹, M. Rani¹, F. Cigarroa¹
¹UT Health San Antonio, San Antonio, TX, ²University Health, San Antonio, TX
*Purpose: Hospital bed capacity and patient throughput are persistent challenges for medical centers. One established strategy for increasing patient throughput and decompressing Emergency Departments is…
2021 American Transplant Congress
The Role of Donor-derived Cell-free DNA to Detect Subclinical Acute Rejection in Kidney Allograft
S. Park¹, K. Guo², R. Heilman³, E. Poggio⁴, D. Taber⁵, C. Marsh⁶, S. Kurian⁷, S. Kleiboeker⁸, J. Weems⁹, J. Holman¹⁰, L. Zhao², R. Sinha⁸, S. Brietigam², C. Rebello², M. Abecassis¹¹, J. Friedewald¹
¹Transplant nephrology, Northwestern University, Chicago, IL, ²Feinberg School of Medicine, Northwestern University, Chicago, IL, ³Transplant nephrology, Mayo Clinic College of Medicine and Science, Phoenix, AZ, ⁴Department of Nephrology and Hypertension, Cleveland Clinic, Cleveland, OH, ⁵Division of Transplant Surgery, Medical University of South Carolina, Charleston, SC, ⁶Department of Medicine and Surgery, Scripps Clinic and Green Hospital, La Jolla, CA, ⁷Scripps Health, La Jolla, CA, ⁸Eurofins US Clinical Diagnostics, Lee's Summit, MO, ⁹Eurofins US Clinical Diagnostics, Lee’s Summit, MO, ¹⁰Transplant Genomics, Inc, Mansfield, MA, ¹¹University of Arizona College of Medicine, Northwestern University, Tucson, AZ
*Purpose: We hypothesized that donor-derived cell-free DNA (dd-cfDNA) could detect subclinical acute rejection (subAR).*Methods: 429 blood samples paired with surveillance kidney biopsies from 208 patients…
2021 American Transplant Congress
Inflammation in Scarred Cortex (i-IFTA) is Significantly Associated with T Cell-mediated Rejection (TCMR), but Not Antibody-mediated Rejection (ABMR), in Renal Allograft Biopsies (Bx)
H. Zhang
Transplant Immunology Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: I-IFTA in renal allograft Bx has been found to be associated with decreased death-censored graft survival. Moderate to severe i-IFTA (2 or 3) is…

1
2
3
…
139
Next Page »